Clinical trials: Kidney Transplant
Kidney Transplantation in Highly Sensitized Patients
A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to Transplantation
The purpose of this study is to assess whether imlifidase in combination with bortezomib, belatacept, rituximab and IVIg can suppress donor specific antibodies (DSA) and the occurrence of antibody-mediated rejection (AMR) in…
- Trial name
- NCT05049850
- Testing
- Imlifidase
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Hansa Biopharma AB
Liver Transplantation, Kidney Transplantation
Enhancing Donated After Cardiac Death (DCD) Utilization With Thrombolytic Therapy
We hypothesize that delayed graft function and ITBS events may be related to small blood clots (microthrombi) that collect in the kidneys and liver after cardiac death.
- Trial name
- NCT01197573
- Testing
- rTPA Treatment, No TPA Treatment
- Where
- 2 sites in United States
- Volunteers
- 103 people
- Sponsor
- The Cleveland Clinic
Kidney Transplantation, Kidney Diseases
CamTac Trial:Campath-Tacrolimus vs IL2R MoAb/Tacrolimus/MMF in Renal Transplantation
The advent of new, potent immunosuppressive (anti-rejection) drugs over the past ten years has substantially reduced the risk of rejection after kidney transplantation, has allowed the development of immuno-suppressive regimens…
- Conditions
- Kidney Transplantation, Kidney Diseases, Kidney Failure
- Trial name
- NCT00246129
- Testing
- Campath, Daclizumab
- Where
- United Kingdom
- Volunteers
- 123 people
- Sponsor
- EMagnusson
Kidney Transplant
Sotagliflozin Safety and Tolerability Among Renal Transplant Recipients
This is an investigator-initiated, randomized controlled trial in adult KTRs (N=50) with stable allograft function to assess: 1) the reversibility of the expected acute changes in eGFR with sotagliflozin (donated by Lexicon); 2)…
- Trial name
- START (NCT05405556)
- Testing
- eGFR reporting
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Martina McGrath, MD
Kidney Diseases
Study of ISA247 (Voclosporin) in De Novo Renal Transplantation
This study will see if voclosporin is safe and effective in preventing kidney transplant rejection.
- Trial name
- PROMISE (NCT00270634)
- Testing
- Voclosporin, tacrolimus
- Where
- 45 sites in United States, Canada
- Volunteers
- 334 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
Graft Rejection, Kidney Transplant
Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients
This study will look at the effect on long-term kidney function using tacrolimus right after a transplant and then switching to sirolimus at 3 to 5 months after the transplant.
- Conditions
- Graft Rejection, Kidney Transplant, Renal Allograft Recipients, Renal Transplant
- Trial name
- NCT00895583
- Testing
- Tacrolimus, Sirolimus
- Where
- 44 sites in United States, Argentina and 5 more
- Volunteers
- 254 people
- Sponsor
- Pfizer
BK Virus Infection
A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients
This clinical research study will test the safety and efficacy of the investigational medication MAU868, compared to a placebo, in patients who have had a kidney transplant who have active BK virus.
- Trial name
- NCT04294472
- Testing
- MAU868
- Where
- 18 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Vera Therapeutics, Inc.
Kidney Transplant
Pharmacokinetics, Safety and Tolerability of Single-dose Belatacept in Adolescent Kidney Transplant Recipients
The purpose of this study is to evaluate how well adolescent kidney transplant patients tolerate a single dose of belatacept they receive at least 6 months after transplant surgery, and how their body handles the drug.
- Trial name
- NCT01791491
- Testing
- Belatacept
- Where
- 8 sites in United States
- Volunteers
- 16 people
- Sponsor
- Bristol-Myers Squibb
Medication Adherence, Liver Transplantation
A Study of mDOT for Immunosuppressant Adherence in Solid Organ Transplant Recipients
In solid organ transplant recipients, poor adherence to immunosuppressant medications carries the risk of graft rejection (needing a new transplant), post-transplant complications, and increased healthcare costs.
- Conditions
- Medication Adherence, Liver Transplantation, Kidney Transplantation
- Trial name
- NCT04587024
- Testing
- mHealth intervention, standard of care
- Where
- 2 sites in United States
- Volunteers
- 75 people
- Sponsor
- Johns Hopkins University
Quality of Life, End Stage Renal Disease
Improved Selection of Elderly (> 65 Years) for Kidney Transplantation
Kidney transplantation has been shown to provide improved survival even in patients older than 70 years of age. The purpose of the study is to determine whether kidney transplantation provides any improvement of health related…
- Conditions
- Quality of Life, End Stage Renal Disease, End Stage Renal Failure on Dialysis
- Trial name
- QUESTION65 (NCT01760733)
- Where
- Norway
- Volunteers
- 289 people
- Sponsor
- Sykehuset Telemark
Transplants and Implants
Myfortic or CellCept Gastrointestinal Effects in African American Kidney Recipients
Myfortic (enteric-coated mycophenolate sodium) has been shown to have similar effectiveness to CellCept (mycophenolate mofetil) in preventing rejection in kidney transplant recipients.
- Trial name
- NCT00522548
- Testing
- Enteric coated mycophenolate sodium, Mycophenolate mofetil
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Pennsylvania
Hepatorenal Syndrome
Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline
Pentoxyfylline therapy in addition to the standard of care of albumin, midodrine and octreotide therapy is superior to the standard of care alone in the treatment of Type I hepatorenal syndrome in the first 14 days of…
- Trial name
- NCT02123576
- Testing
- Pentoxyfylline, AMO Therapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Patrick Northup, MD
End-stage Renal Failure, Graft Rejection
Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction in Kidney Transplantation
The current anti-rejection drug regime for kidney transplant recipients in use at the West London Renal \& Transplant Centre (WLRaTC) consists of induction therapy with the very potent monoclonal antibody Campath 1-H…
- Trial name
- TAESR (NCT00807144)
- Testing
- Tacrolimus (Kidney transplant maintenance immunosuppression), Kidney transplant maintenance immunosuppression
- Where
- United Kingdom
- Volunteers
- 102 people
- Sponsor
- Imperial College Healthcare NHS Trust
Kidney Transplant Immunosuppression
Use of DNA Testing to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression
The purpose of the study is to identify kidney transplant patients that can be transitioned from multi-drug immunosuppression therapy to Belatacept monotherapy, using cell free DNA and gene expression as markers of immune…
- Trial name
- NCT04786067
- Testing
- Belatacept
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Texas Southwestern Medical Center
FSGS, Proteinuria
Rituximab to Prevent Recurrence of Proteinuria
The investigators propose to study novel targets of rituximab in podocytes, with a particular focus on recurrent focal segmental glomerulosclerosis (FSGS).
- Trial name
- NCT01164098
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- George W. Burke
HIV Infections, Renal Transplant Rejection
Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant
This is an open-label study, where participants will be switched from their current HIV medication to the study drug, BIC/F/TAF. Open-label means both the investigator and the participant will know what drug will be given.
- Trial name
- NCT04530630
- Testing
- BIC/F/TAF 50Mg-200Mg-25Mg Tablet
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Weill Medical College of Cornell University
Cardiovascular Disease, Chronic Kidney Disease
Vascular Risk After Kidney Transplantation
Hypothesis: Nontraditional risk factors, such as inflammation, vitamin D deficiency, elevated PTH, insulin resistance, homocysteine, or uric acid, contribute to cardiovascular disease progression after kidney transplant.
- Conditions
- Cardiovascular Disease, Chronic Kidney Disease, Diabetes, Vitamin D Deficiency
- Trial name
- NCT00374595
- Where
- United States
- Volunteers
- 338 people
- Sponsor
- University of Nebraska
Kidney Transplant, Kidney Transplant; Complications
The Use of a Consumer-Based mHealth Dietary App and Health Coaching With Kidney Transplant Recipients
The purpose of the study is to test the feasibility mHealth dietary app + health coaching for improving primary outcomes (recruitment, retention, and adherence) and secondary outcomes (perceived stress [ Perceived Stress Scale]…
- Trial name
- TASK (NCT05151445)
- Testing
- mHealth dietary app + health coaching intervention
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Ohio State University
Kidney Transplantation
Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients
The purpose of this study was to determine whether an early Calcineurin Inhibitor (CNI) to everolimus conversion at 10-14 weeks post transplantation improves renal allograft function without compromising efficacy compared to…
- Trial name
- ELEVATE (NCT01114529)
- Testing
- Everolimus, Prograf or Neoral
- Where
- 77 sites in Argentina, Australia and 19 more
- Volunteers
- 828 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation
The purpose of this trial is to assess the immune response after vaccination with a peptide vaccine called galinpepimut-S (or GPS) in a type of blood cancer called multiple myeloma.
- Trial name
- NCT01827137
- Testing
- Galinpepimut-S, GM-CSF, Montanide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sellas Life Sciences Group